Loading clinical trials...

Study of BLU-808 in Allergic Rhinoconjunctivitis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study of BLU-808 in Allergic Rhinoconjunctivitis

A Phase 2a Randomized Double-blinded Placebo Controlled Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Clinical Activity of BLU-808, a Wild-type KIT Inhibitor, in Participants With Ragweed (Ambrosia Artemisiifolia)-Induced Allergic Rhinoconjunctivitis

NCT06922448•Blueprint Medicines Corporation

View on ClinicalTrials.gov

Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (ARC). Participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (AEC).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Adults, 18 years of age or older, willing to provide written informed consent, and willing to comply with all study requirements.
•2. History (\>2 years) of ragweed-induced ARC.
•3. A positive ragweed skin prick test (mean diameter of ≥ 5 mm) in the last 6 months.
•4. Must meet clinically relevant nasal and ocular symptoms as defined by the protocol.

Exclusion Criteria

•Participants are excluded from the study if any of the following criteria are met:
•1. Receiving medications (oral, nasal, topical, ocular, or injectable) to treat their ragweed or other allergy symptoms and/or receiving any medications that impact participants' safety or interfere with study assessments or interpretation of study results.
•2. Have active rhinitis, sinusitis, and/or other severe allergies not associated with the ragweed pollen that may interfere with study symptom assessments.
•3. Any prior or ongoing clinically significant illness, medical or psychiatric condition, surgical history, or physical finding that may interfere with the assessment or interpretation of study results.
•4. Clinically significant moderate to severe, uncontrolled cardiovascular, renal or hepatic disease.
•5. Significant bleeding risk or coagulation disorders.
•6. Any form of smoking, vaping or history of alcohol and drug abuse.
•7. Any malignancy within the past 5 years prior to Screening/AEC 1, except for basal cell or squamous cell carcinomas of the skin or carcinoma in situ.
•8. Inadequately controlled asthma that could affect the safety of the participant or interfere with the assessment or interpretation of study results.
•9. Known active/latent infection (viral, bacterial, fungal, helminth, or mycobacterial) such as tuberculosis, hepatitis B, hepatitis C, AIDS-related illness, or COVID-19 infection.
+1 more criteria

Locations (1)

Red Maple Trials

Ottawa, Canada

Key Dates

Start Date

April 14, 2025

Primary Completion Date

September 8, 2025

Completion Date

September 8, 2025

Last Updated

February 10, 2026

Enrollment

ACTUAL participants

Conditions

Allergic Rhinoconjunctivitis

Interventions

BLU-808

DRUG

Placebo

DRUG

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

NCT06778213

Allergic Rhinoconjunctivitis

View study

COMPLETEDPHASE2

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

NCT04502966

Allergic RhinoconjunctivitisGrass Pollen Allergy

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of BLU-808 in Allergic Rhinoconjunctivitis

Inclusion Criteria

Exclusion Criteria

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics